← Back to patent-cliff list
Donidalorsen
Tier C — Watch / tradeDonidalorsen
Ionis Pharmaceuticals Inc
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：Kallikreins
Brand：DAWNZERA
Indications (approved)：遗传性血管性水肿
Regional status
US
Approved
2025-08-21
EU
Approved
2026-01-19
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Donidalorsen?
Approved indications include: 遗传性血管性水肿.
When does the Donidalorsen patent expire?
No public expiry year is available for Donidalorsen yet; this page updates once verified.
How do I get a quote for Donidalorsen intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01